 | • レポートコード：D0GIR-01675 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、血液悪性腫瘍におけるCAR-T療法の世界市場を広く調査・分析し、今後の市場展望をまとめております。血液悪性腫瘍におけるCAR-T療法の種類別市場規模（同種、自己）、用途別市場規模（病院、がん研究センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Celgene (Juno Therapeutics)、Sorrento Therapeutics、Pfizer、Novartis、Aurora BioPharma、Gilead (Kite Pharma)、Bluebird Bio、Autolus Therapeutics、CARsgen Therapeutics、Mustang Bio、Collectis、Allogene Therapeutics、Celyad ・地域別グローバル市場分析 2015年-2020年 ・血液悪性腫瘍におけるCAR-T療法の北米市場（アメリカ、カナダ、メキシコ） ・血液悪性腫瘍におけるCAR-T療法のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・血液悪性腫瘍におけるCAR-T療法のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・血液悪性腫瘍におけるCAR-T療法の南米市場（ブラジル、アルゼンチン） ・血液悪性腫瘍におけるCAR-T療法の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：同種、自己 ・用途別分析：病院、がん研究センター、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The CAR-T Therapy in Haematological Malignancy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global CAR-T Therapy in Haematological Malignancy sales will be xx in 2020 from CAR-T Therapy in Haematological Malignancy million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global CAR-T Therapy in Haematological Malignancy market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the CAR-T Therapy in Haematological Malignancy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on CAR-T Therapy in Haematological Malignancy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
CAR-T Therapy in Haematological Malignancy market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, CAR-T Therapy in Haematological Malignancy market has been segmented into:
Allogeneic
Autologous
By Application, CAR-T Therapy in Haematological Malignancy has been segmented into:
Hospitals
Cancer Research Centers
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global CAR-T Therapy in Haematological Malignancy market presented in the report. This section sheds light on the sales growth of different regional and country-level CAR-T Therapy in Haematological Malignancy markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global CAR-T Therapy in Haematological Malignancy market.
The report offers in-depth assessment of the growth and other aspects of the CAR-T Therapy in Haematological Malignancy market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and CAR-T Therapy in Haematological Malignancy Market Share Analysis
CAR-T Therapy in Haematological Malignancy competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, CAR-T Therapy in Haematological Malignancy sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the CAR-T Therapy in Haematological Malignancy sales, revenue and market share for each player covered in this report.
The major players covered in CAR-T Therapy in Haematological Malignancy are:
Celgene (Juno Therapeutics)
Sorrento Therapeutics
Pfizer
Novartis
Aurora BioPharma
Gilead (Kite Pharma)
Bluebird Bio
Autolus Therapeutics
CARsgen Therapeutics
Mustang Bio
Collectis
Allogene Therapeutics
Celyad
Among other players domestic and global, CAR-T Therapy in Haematological Malignancy market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 CAR-T Therapy in Haematological Malignancy Market Overview
1.1 Product Overview and Scope of CAR-T Therapy in Haematological Malignancy
1.2 Classification of CAR-T Therapy in Haematological Malignancy by Type
1.2.1 Global CAR-T Therapy in Haematological Malignancy Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type in 2019
1.2.3 Allogeneic
1.2.4 Autologous
1.3 Global CAR-T Therapy in Haematological Malignancy Market by Application
1.3.1 Overview: Global CAR-T Therapy in Haematological Malignancy Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Others
1.4 Global CAR-T Therapy in Haematological Malignancy Market by Regions
1.4.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of CAR-T Therapy in Haematological Malignancy (2015-2025)
1.4.3 North America (USA, Canada and Mexico) CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) CAR-T Therapy in Haematological Malignancy Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: CAR-T Therapy in Haematological Malignancy Industry Impact
1.5.1 COVID-19 Potential Implications for the CAR-T Therapy in Haematological Malignancy
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on CAR-T Therapy in Haematological Malignancy
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Celgene (Juno Therapeutics)
2.1.1 Celgene (Juno Therapeutics) Details
2.1.2 Celgene (Juno Therapeutics) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Celgene (Juno Therapeutics) SWOT Analysis
2.1.4 Celgene (Juno Therapeutics) Product and Services
2.1.5 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sorrento Therapeutics
2.2.1 Sorrento Therapeutics Details
2.2.2 Sorrento Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sorrento Therapeutics SWOT Analysis
2.2.4 Sorrento Therapeutics Product and Services
2.2.5 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.5 Aurora BioPharma
2.5.1 Aurora BioPharma Details
2.5.2 Aurora BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Aurora BioPharma SWOT Analysis
2.5.4 Aurora BioPharma Product and Services
2.5.5 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.6 Gilead (Kite Pharma)
2.6.1 Gilead (Kite Pharma) Details
2.6.2 Gilead (Kite Pharma) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Gilead (Kite Pharma) Product and Services
2.6.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.7 Bluebird Bio
2.7.1 Bluebird Bio Details
2.7.2 Bluebird Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Bluebird Bio Product and Services
2.7.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.8 Autolus Therapeutics
2.8.1 Autolus Therapeutics Details
2.8.2 Autolus Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Autolus Therapeutics Product and Services
2.8.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.9 CARsgen Therapeutics
2.9.1 CARsgen Therapeutics Details
2.9.2 CARsgen Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 CARsgen Therapeutics Product and Services
2.9.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.10 Mustang Bio
2.10.1 Mustang Bio Details
2.10.2 Mustang Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Mustang Bio Product and Services
2.10.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.11 Collectis
2.11.1 Collectis Details
2.11.2 Collectis Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Collectis Product and Services
2.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.12 Allogene Therapeutics
2.12.1 Allogene Therapeutics Details
2.12.2 Allogene Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Allogene Therapeutics Product and Services
2.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
2.13 Celyad
2.13.1 Celyad Details
2.13.2 Celyad Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Celyad Product and Services
2.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global CAR-T Therapy in Haematological Malignancy Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 CAR-T Therapy in Haematological Malignancy Players Market Share
3.2.2 Top 10 CAR-T Therapy in Haematological Malignancy Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global CAR-T Therapy in Haematological Malignancy Revenue and Market Share by Regions
4.2 North America CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
4.3 Europe CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
4.5 South America CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
5 North America CAR-T Therapy in Haematological Malignancy Revenue by Countries
5.1 North America CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
5.2 USA CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
5.3 Canada CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
5.4 Mexico CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
6 Europe CAR-T Therapy in Haematological Malignancy Revenue by Countries
6.1 Europe CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
6.2 Germany CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
6.3 UK CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
6.4 France CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
6.5 Russia CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
6.6 Italy CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
7 Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue by Countries
7.1 Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
7.2 China CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
7.3 Japan CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
7.4 Korea CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
7.5 India CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
8 South America CAR-T Therapy in Haematological Malignancy Revenue by Countries
8.1 South America CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
8.2 Brazil CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
8.3 Argentina CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue CAR-T Therapy in Haematological Malignancy by Countries
9.1 Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
9.2 Saudi Arabia CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
9.3 UAE CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
9.4 Egypt CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
9.5 South Africa CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global CAR-T Therapy in Haematological Malignancy Revenue and Market Share by Type (2015-2020)
10.2 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Type (2019-2024)
10.3 Allogeneic Revenue Growth Rate (2015-2025)
10.4 Autologous Revenue Growth Rate (2015-2025)
11 Global CAR-T Therapy in Haematological Malignancy Market Segment by Application
11.1 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application (2015-2020)
11.2 CAR-T Therapy in Haematological Malignancy Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Cancer Research Centers Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast (2021-2025)
12.1 Global CAR-T Therapy in Haematological Malignancy Market Size Forecast (2021-2025)
12.2 Global CAR-T Therapy in Haematological Malignancy Market Forecast by Regions (2021-2025)
12.3 North America CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
12.4 Europe CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
12.6 South America CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of CAR-T Therapy in Haematological Malignancy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market CAR-T Therapy in Haematological Malignancy Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Celgene (Juno Therapeutics) Corporate Information, Location and Competitors
Table 7. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Major Business
Table 8. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 9. Celgene (Juno Therapeutics) SWOT Analysis
Table 10. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 11. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Sorrento Therapeutics Corporate Information, Location and Competitors
Table 13. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Major Business
Table 14. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2018-2019)
Table 15. Sorrento Therapeutics SWOT Analysis
Table 16. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 17. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Pfizer Corporate Information, Location and Competitors
Table 19. Pfizer CAR-T Therapy in Haematological Malignancy Major Business
Table 20. Pfizer CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 21. Pfizer SWOT Analysis
Table 22. Pfizer CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 23. Pfizer CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Novartis Corporate Information, Location and Competitors
Table 25. Novartis CAR-T Therapy in Haematological Malignancy Major Business
Table 26. Novartis CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 27. Novartis SWOT Analysis
Table 28. Novartis CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 29. Novartis CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Aurora BioPharma Corporate Information, Location and Competitors
Table 31. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Major Business
Table 32. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 33. Aurora BioPharma SWOT Analysis
Table 34. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 35. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Gilead (Kite Pharma) Corporate Information, Location and Competitors
Table 37. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Major Business
Table 38. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 39. Gilead (Kite Pharma) SWOT Analysis
Table 40. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 41. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Bluebird Bio Corporate Information, Location and Competitors
Table 43. Bluebird Bio CAR-T Therapy in Haematological Malignancy Major Business
Table 44. Bluebird Bio CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 45. Bluebird Bio SWOT Analysis
Table 46. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 47. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Autolus Therapeutics Corporate Information, Location and Competitors
Table 49. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Major Business
Table 50. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 51. Autolus Therapeutics SWOT Analysis
Table 52. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 53. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. CARsgen Therapeutics Corporate Information, Location and Competitors
Table 55. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Major Business
Table 56. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 57. CARsgen Therapeutics SWOT Analysis
Table 58. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 59. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Mustang Bio Corporate Information, Location and Competitors
Table 61. Mustang Bio CAR-T Therapy in Haematological Malignancy Major Business
Table 62. Mustang Bio CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 63. Mustang Bio SWOT Analysis
Table 64. Mustang Bio CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 65. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Collectis Corporate Information, Location and Competitors
Table 67. Collectis CAR-T Therapy in Haematological Malignancy Major Business
Table 68. Collectis CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 69. Collectis SWOT Analysis
Table 70. Collectis CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 71. Collectis CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Allogene Therapeutics Corporate Information, Location and Competitors
Table 73. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Major Business
Table 74. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 75. Allogene Therapeutics SWOT Analysis
Table 76. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 77. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. Celyad Corporate Information, Location and Competitors
Table 79. Celyad CAR-T Therapy in Haematological Malignancy Major Business
Table 80. Celyad CAR-T Therapy in Haematological Malignancy Total Revenue (USD Million) (2017-2018)
Table 81. Celyad SWOT Analysis
Table 82. Celyad CAR-T Therapy in Haematological Malignancy Product and Solutions
Table 83. Celyad CAR-T Therapy in Haematological Malignancy Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) by Players (2015-2020)
Table 85. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Players (2015-2020)
Table 86. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) by Regions (2015-2020)
Table 87. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Regions (2015-2020)
Table 88. North America CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
Table 89. North America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 90. Europe CAR-T Therapy in Haematological Malignancy Revenue (Million USD) by Countries (2015-2020)
Table 91. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue (Million USD) by Countries (2015-2020)
Table 92. South America CAR-T Therapy in Haematological Malignancy Revenue by Countries (2015-2020)
Table 93. South America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 94. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue (Million USD) by Countries (2015-2020)
Table 95. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Table 96. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) by Type (2015-2020)
Table 97. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Type (2015-2020)
Table 98. Global CAR-T Therapy in Haematological Malignancy Revenue Forecast by Type (2021-2025)
Table 99. Global CAR-T Therapy in Haematological Malignancy Revenue by Application (2015-2020)
Table 100. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Application (2015-2020)
Table 101. Global CAR-T Therapy in Haematological Malignancy Revenue Forecast by Application (2021-2025)
Table 102. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. CAR-T Therapy in Haematological Malignancy Picture
Figure 2. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type in 2019
Figure 3. Allogeneic Picture
Figure 4. Autologous Picture
Figure 5. CAR-T Therapy in Haematological Malignancy Revenue Market Share by Application in 2019
Figure 6. Hospitals Picture
Figure 7. Cancer Research Centers Picture
Figure 8. Others Picture
Figure 9. Global CAR-T Therapy in Haematological Malignancy Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Players in 2019
Figure 17. Global Top 5 Players CAR-T Therapy in Haematological Malignancy Revenue Market Share in 2019
Figure 18. Global Top 10 Players CAR-T Therapy in Haematological Malignancy Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Regions (2015-2020)
Figure 22. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Regions in 2018
Figure 23. North America CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 24. Europe CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 26. South America CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 28. North America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Figure 29. North America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries in 2019
Figure 30. USA CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 31. Canada CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 32. Mexico CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 33. Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Figure 34. Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries in 2019
Figure 35. Germany CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 36. UK CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 37. France CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 38. Russia CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 39. Italy CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries in 2019
Figure 42. China CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 43. Japan CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 44. Korea CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 45. India CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 47. South America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Figure 48. South America CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries in 2019
Figure 49. Brazil CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 50. Argentina CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 54. UAE CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 55. Egypt CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 56. South Africa CAR-T Therapy in Haematological Malignancy Revenue and Growth Rate (2015-2020)
Figure 57. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Type (2015-2020)
Figure 58. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Type in 2019
Figure 59. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Type (2021-2025)
Figure 60. Global Allogeneic Revenue Growth Rate (2015-2020)
Figure 61. Global Autologous Revenue Growth Rate (2015-2020)
Figure 62. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Application (2015-2020)
Figure 63. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Application in 2019
Figure 64. Global CAR-T Therapy in Haematological Malignancy Market Share Forecast by Application (2021-2025)
Figure 65. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 66. Global Cancer Research Centers Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global CAR-T Therapy in Haematological Malignancy Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
Figure 72. Europe CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
Figure 74. South America CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa CAR-T Therapy in Haematological Malignancy Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
心臓再同期療法（CRT）の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Cardiac Resynchronization Therapy (CRT) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.3% in the forecast period of 2020 to 2025 and will expected to reach USD 5790.2 million by 2025, from USD 4895.2 million in 2019. …- 理学療法サービスの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Physical Therapy Services market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Physical Therapy Se…
- 注射型標的療法の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Injectable Targeted Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiz…
- mRNA療法の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The mRNA Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade re…
- がん輸液療法の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Cancer Infusion Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…